Portable Therapeutic Fluid Delivery Device for Concurrent Insulin and Amylin Administration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diabetic management devices cannot concurrently deliver insulin and additional anti-diabetic agents like amylin analogs, leading to poor compliance due to separate injection requirements, which complicates glycemic control and increases the risk of post-prandial hyperglycemia.
Innovation Solution
A portable therapeutic fluid delivery device that includes a system for simultaneously dispensing insulin and a second anti-diabetic agent, such as pramlintide, using a closed-loop system that adjusts dosages based on glucose levels, allowing for concomitant delivery through a shared or independent cannula and pumping mechanism, with a sensor for continuous glucose monitoring and remote control functionality.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If separate injection devices are used for insulin and anti-diabetic agents, then each drug can be delivered independently, but patient compliance deteriorates due to multiple injection requirements
Solution Approach 1:
The patent combines multiple drug delivery functions into a single injection device that can simultaneously or sequentially deliver insulin and anti-diabetic agents through a single injection site, eliminating the need for multiple separate injections and thereby improving patient compliance while maintaining reliable glycemic control
Solution Approach 2:
The injection device is designed with multi-functionality to deliver different types of anti-diabetic medications (insulin, GLP-1 analogs, amylin analogs, or combinations thereof) through a single device, allowing flexible dosing regimens while simplifying the treatment process for patients
2Manufacturing precision
If multiple separate devices are used for drug delivery, then dosing accuracy for each drug is maintained, but device complexity increases
Solution Approach 1:
The device incorporates separate controllable delivery mechanisms for each drug type within a single integrated unit, allowing independent dosing control for insulin and anti-diabetic agents while maintaining physical integration to reduce overall device complexity
Solution Approach 2:
The patent employs a microprocessor-based control system as an intermediary to manage the complex dosing algorithms and coordination between multiple drug delivery mechanisms, simplifying the control architecture while maintaining precise dosing accuracy for each medication
3Reliability
If concomitant delivery of insulin and anti-diabetic agents is implemented, then post-prandial hyperglycemia control is improved, but the pumping mechanism complexity increases
Solution Approach 1:
The device is designed to deliver drugs in periodic sequences coordinated with meal timing, where insulin and anti-diabetic agents are administered at specific intervals before and after meals to effectively control post-prandial glucose excursions while using a coordinated pumping strategy
Solution Approach 2:
The pumping mechanism incorporates dynamic control capabilities that adjust delivery rates and timing based on real-time glucose sensor feedback and predetermined dosing algorithms, allowing the system to adapt dosing parameters while maintaining a unified pumping architecture
Data Source
Figure 1~2
Figure 3a~3b
Figure 4a
AI summary
Delivery of more than one therapeutic fluid as a means to control symptoms of a health conditions is disclosed. More than one therapeutic fluid may be dispensed from more than one reservoir and delivered to a user' s body via one or more cannula that penetrate the skin. The therapeutic fluids may be delivered by action of one or more pumping mechanisms that may be controlled by a processor in a portable, ambulatory device. The therapeutic fluids may optionally be insulin and one or more of an amylin analog, pramlintide acetate and an exenatide, and the health condition may optionally be diabetes. This device can be used in combination with a glucometer.